Duchesnay Pharmaceutical Group

What Duchesnay Pharmaceutical Group does

Duchesnay Pharmaceutical Group is a privately-held Canadian pharmaceutical company headquartered in Blainville, Quebec, operating through six wholly-owned commercial entities spanning women's health, rare diseases, and generic orphan drugs. The group manufactures pharmaceutical products at its Blainville facility (expanded in 2025 with a new tablet printer and a second production shift) and distributes through dedicated Canadian and US commercial arms, including a Princeton, New Jersey US operation. Following a 2021 management buyout, the company operates as a vertically integrated specialty pharma platform serving patients across North America and 40+ international markets via out-licensing partnerships.

The company's core portfolio includes Diclectin (doxylamine succinate and pyridoxine hydrochloride combination) for nausea and vomiting of pregnancy, PregVit prenatal vitamin formulations, Siklos (hydroxyurea) for sickle cell disease, and Pheburane (sodium phenylbutyrate) for urea cycle disorders. The Analog Pharma platform extends the model into affordable generic orphan drugs, with its first Canadian product launched in September 2025. Revenue is generated through direct commercialization of branded and generic products across six commercial entities in Canada and the United States, supplemented by royalty income from out-licensing the NVP treatment portfolio to partners in more than 40 countries. Market access efforts have secured Medicaid coverage for Pheburane across 19 US states with limited restrictions in 29 states, reflecting a deliberate payer access strategy in orphan drug channels.

The company was selected for Canada's Global Hypergrowth Project cohort in July 2023 and has received ADRIQ Life-Sciences Innovation and Bernard-Landry awards in 2024, reflecting a growth-stage posture focused on international expansion, generic product extensions, and capacity scaling. Distribution reaches patients through field sales organizations targeting healthcare providers, supported by dedicated rare disease and women's health commercial teams operating in both countries. With 51-100 employees and in-house manufacturing, the company combines proprietary formulation development (6+ patents held by President Éric Gervais) with in-licensing and out-licensing capabilities to sustain a multi-therapeutic specialty pharma platform.

Name

Duchesnay Pharmaceutical Group

Legal name

Duchesnay Pharmaceutical Group Inc.

Website

https://duchesnaypharmaceuticalgroup.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Duchesnay Pharmaceutical Group is a privately-held Canadian pharmaceutical company operating six entities that develop, manufacture, and commercialize branded and generic drugs in women's health, rare diseases, and orphan drugs across Canada, the United States, and 40+ international markets.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Patent Owners & Lessors (6794)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Women's health pharmaceuticals
• Rare disease treatments
• Specialty pharmaceuticals
• Generic orphan drugs
• Pharmaceutical manufacturing

Headquarters

HQ city

Blainville

HQ country

Canada

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Product Sales (In-licensing): DPG commercializes branded and generic products for the Canadian and U.S. marketplace through its six entities. This includes women's health products (Duchesnay Canada/USA), rare disease treatments (Medunik Canada/USA), and generic orphan drugs (Analog Pharma Canada/USA).
2. Out-licensing Royalties: Duchesnay out-licenses its in-house developed, manufactured and patented treatment portfolio for nausea and vomiting of pregnancy (NVP) in over 40 countries. The unique product portfolio features two formulations combining doxylamine succinate and pyridoxine hydrochloride available under different strengths and formulations.
3. Specialty Pharmaceutical Products: Medunik USA provides Siklos (hydroxyurea) for sickle cell disease and Pheburane (sodium phenylbutyrate) for urea cycle disorders with expanded Medicaid coverage and patient support programs to improve access.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Duchesnay Pharmaceutical Group is a Canadian specialty pharmaceutical company that develops, manufactures, and commercializes treatments primarily in women's health and rare diseases. The group operates six entities (Duchesnay Canada, Duchesnay USA, Analog Pharma Canada, Analog Pharma USA, CENEXI, and Verity Pharma) and supports its products through out-licensing in 40+ countries and in-licensing arrangements.

Product overview

Duchesnay Pharmaceutical Group (DPG) is a Canadian-based multinational pharmaceutical group composed of 6 entities operating internationally. The company operates as a platform of specialized pharmaceutical companies: Duchesnay Canada and Duchesnay USA focus on women's health; Médunik Canada and Medunik USA focus on rare diseases; and Analog Pharma Canada and Analog Pharma USA focus on affordable generic orphan drugs. The core product portfolio includes PrDiclectin® (flagship drug for nausea and vomiting of pregnancy), PregVit formulations, Siklos® (for sickle cell disease), and Pheburane® (for urea cycle disorders). DPG exports treatments to over 50 countries across Europe, North and South America, and Asia.

Differentiator

Problem solved

Functional benefit

Brands

• PrDiclectin: Flagship drug for managing nausea and vomiting of pregnancy (NVP), combining doxylamine succinate and pyridoxine hydrochloride
• PregVit
• PregVit folic 5
• Pheburane
• Siklos

Products and services

• Diclectin Diclectin is a branded prescription combination of doxylamine and pyridoxine indicated for the management of nausea and vomiting of pregnancy. It is sold to healthcare providers and patients through Duchesnay's Canadian and US commercial entities.
• ALOG-Doxylamine/Pyridoxine (Generic) ALOG-Doxylamine/Pyridoxine is the generic version of Diclectin (doxylamine/pyridoxine), launched in 2025 by Analog Pharma Canada to provide an affordable treatment option for nausea and vomiting of pregnancy.
• PregVit PregVit is a prescription prenatal vitamin formulated for use before, during, and after pregnancy, marketed to obstetricians, family physicians, and pregnant patients.
• PregVit folic 5 PregVit folic 5 is a higher-dose folic acid prenatal vitamin variant in the PregVit line, targeted at women requiring elevated folate intake before and during pregnancy.
• Siklos Siklos (hydroxyurea) is an orphan-disease therapy indicated for the treatment of sickle cell disease, sold to hematologists, specialist centers, and rare-disease patient communities in markets where Duchesnay holds rights.
• Pheburane Pheburane (sodium phenylbutyrate) is an orphan drug indicated for the treatment of urea cycle disorders, distributed to metabolic specialists and rare-disease treatment centers.
• Concilivi Concilivi is a Duchesnay pharmaceutical product approved and marketed in Canada, contributing to the group's specialty product portfolio.

Quantifiable outcome

• Nearly 100,000 Americans with sickle cell disease supported with Siklos treatment
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• International Research OrganizationscoreStrategic or Co-development PartnerDPG collaborates closely with renowned international research and academia organizations, fostering exchange of ideas and accelerating development of innovative therapies. The company works with medical communities specializing in rare diseases and women's health.
• Healthcare Providers and Medical CommunitiescoreStrategic or Co-development PartnerDPG works with the medical community both in Canada and abroad. Medunik Canada collaborates closely with medical communities specializing in inherited metabolic diseases. The company integrates field and clinical investigations with healthcare providers.
• Licensing Partners (In-licensing)coreTechnology or IntegrationDPG serves as a trusted partner to commercialize branded and generic products for patients in Canadian and/or U.S. marketplace, focusing on women's health, rare diseases, brand and generic treatment options.
• Licensing Partners (Out-licensing)coreOEM/ Whitelabel/ Licensing PartnerDuchesnay out-licenses its in-house developed, manufactured and patented treatment portfolio for nausea and vomiting of pregnancy (NVP) in over 40 countries. The portfolio features two formulations combining doxylamine succinate and pyridoxine hydrochloride.
• Global Hypergrowth Project (GHP)majorStrategic or Co-development PartnerDPG is part of the first cohort selected for the Global Hypergrowth Project, a pioneering initiative of the federal government (Innovation, Science and Economic Development Canada). This partnership positions DPG among Canadian companies with high growth potential.
• Local Non-profit OrganizationsminorOthersDPG engages in community support through partnerships with local non-profit organizations, focusing on women's health. The company has faithfully supported Moisson Laurentides for over 12 years and partners with other charitable organizations elected by employees every two years.

Scale indicators8 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Pharmascience: Quebec-based privately held pharmaceutical company that manufactures generic, branded, and OTC products. Comparable as a Canadian-headquartered pharma with own manufacturing and broad product portfolio including women's health and specialty categories.
• Searchlight Pharma: Canadian specialty pharmaceutical company that in-licenses, develops, and commercializes innovative products for Canadian women's health, dermatology, and specialty markets. Closely comparable business model and therapeutic focus.
• Knight Therapeutics: Canadian specialty pharmaceutical company that in-licenses and commercializes branded products across Canada, Latin America, and select international markets. Highly comparable business model to DPG's in-licensing and specialty pharma focus on women's health and rare diseases.
• Theratechnologies: Canadian specialty pharmaceutical company focused on in-licensing and commercializing therapies in women's health, HIV, and rare diseases. Closely aligned therapeutic focus areas and similar mid-size specialty pharma profile.

Broad incumbents

• Perrigo Company: Global consumer-focused pharmaceutical manufacturer of generic Rx, OTC, and specialty products. Comparable to Analog Pharma's strategy of providing affordable medication alternatives, though at significantly larger scale.
• Amneal Pharmaceuticals: US-based pharmaceutical company specializing in generic, specialty, and biosimilar medicines with strong affordable generics focus. Analogous to DPG's Analog Pharma division in delivering affordable medications across diverse therapeutic areas.
• Organon & Co. Global women's health-focused pharmaceutical company spun off from Merck with portfolio across contraception, fertility, and mature brands. Comparable therapeutic focus on women's health with similar product categories like NVP-adjacent treatments.
• Endo International: Specialty pharmaceutical company with portfolio spanning rare diseases, generics, and specialty therapeutics. Comparable business model diversification across branded specialty and generic products.
• Apotex: Largest Canadian-owned generic pharmaceutical manufacturer producing 300+ generics globally. Compares to DPG's Analog Pharma generics arm in product category and geographic reach, though significantly larger scale.
• Vertex Pharmaceuticals: Global biotechnology company with strong rare disease franchise (cystic fibrosis, sickle cell disease). Comparable to DPG's Medunik unit in rare disease focus and orphan drug commercial model, particularly for sickle cell disease treatments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/duchesnay-pharmaceutical-group

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Duchesnay Pharmaceutical Group